Paul S. Jowell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul S. Jowell has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
John Baillie
6 shared publicationsMalcolm S. Branch
6 shared publicationsGail Robuck-Mangum
2 shared publicationsKatrina L. Swartz
2 shared publicationsPoonputt Chotiprasidhi
2 shared publications- Alyson Johnson
Division of Gastroenterology, Duke University School of Medicine, Durham, NC
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (3)
Extranodal Rosai-Dorfman Disease Presenting as a Pancreatic Mass Associated With Superior Mesenteric Artery Thrombosis
Rosai-Dorfman disease (RDD) is a rare, nonmalignant histiocytic disease that classically presents as bulky lymphadenopathy. Although RDD can be seen in various organ systems, gastrointestinal involvement is uncommon. We present a case of RDD involving the pancreatic head causing biliary obstruction, arterial thrombus, abdominal pain, and concern for malignancy. Endoscopic ultrasound and pancreas biopsy demonstrated a mass without malignant features and pathological features including benign pancreatic parenchyma, noncaseating granulomas, and mixed acute and chronic inflammation including histiocytes with emperipolesis and a staining pattern that confirmed a diagnosis of RDD. She experienced symptom relief and reduced mass size and metabolic activity after treatment with cobimetinib. When there is uncertainty surrounding the etiology of a slow-growing pancreatic mass with atypical features, the differential diagnosis should include uncommon causes such as RDD and may warrant evaluation in a tertiary referral center to avoid extensive and unnecessary surgery.
- 1 March 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (3)
Open AccessExtranodal Rosai-Dorfman Disease Presenting as a Pancreatic Mass Associated With Superior Mesenteric Artery Thrombosis
Rosai-Dorfman disease (RDD) is a rare, nonmalignant histiocytic disease that classically presents as bulky lymphadenopathy. Although RDD can be seen in various organ systems, gastrointestinal involvement is uncommon. We present a case of RDD involving the pancreatic head causing biliary obstruction, arterial thrombus, abdominal pain, and concern for malignancy. Endoscopic ultrasound and pancreas biopsy demonstrated a mass without malignant features and pathological features including benign pancreatic parenchyma, noncaseating granulomas, and mixed acute and chronic inflammation including histiocytes with emperipolesis and a staining pattern that confirmed a diagnosis of RDD. She experienced symptom relief and reduced mass size and metabolic activity after treatment with cobimetinib. When there is uncertainty surrounding the etiology of a slow-growing pancreatic mass with atypical features, the differential diagnosis should include uncommon causes such as RDD and may warrant evaluation in a tertiary referral center to avoid extensive and unnecessary surgery.
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB380
Mo1432 Prophylactic Pancreatic Stents: Factors Influencing Migration, and Utility of Aggressive Patient Follow-up
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB380
Mo1432 Prophylactic Pancreatic Stents: Factors Influencing Migration, and Utility of Aggressive Patient Follow-up
- 1 May 2011
- Published by Wolters Kluwer Health in Pancreas
- Vol. 40 (4) , 533-539
Intravenous Synthetic Secretin Reduces the Incidence of Pancreatitis Induced by Endoscopic Retrograde Cholangiopancreatography
This study aimed to evaluate whether synthetic secretin is effective in reducing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. This is a single academic medical center, prospective, randomized, double-blind, placebo-controlled trial using secretin (dose of 16 μg) administered intravenously immediately before ERCP. Patients were evaluated for the primary outcome of post-ERCP pancreatitis as diagnosed by a single investigator. A total of 1100 patients were screened, of whom 869 were randomly assigned to receive secretin (n = 426) or placebo (n = 443) before ERCP and were evaluated after the procedure for efficacy of secretin. The incidence of pancreatitis in the secretin group compared with the placebo group was 36 (8.7%) of 413 patients versus 65 (15.1%) of 431 patients, respectively, P = 0.004. In the subgroup analysis, secretin was highly protective against post-ERCP pancreatitis for patients undergoing biliary sphincterotomy (6/129 vs 32/142, P < 0.001), patients undergoing cannulation of the common bile duct (26/339 vs 56/342, P < 0.001), and patients not undergoing pancreatic sphincterotomy (26/388 vs 57/403, P = 0.001). Analysis of the interaction between these groups reveals that the primary effect of secretin prophylaxis was prevention of post-ERCP pancreatitis in patients undergoing biliary sphincterotomy. Synthetic secretin reduces the risk of post-ERCP pancreatitis, particularly in patients in undergoing biliary sphincterotomy.
- 1 May 2011
- Published by Wolters Kluwer Health in Pancreas
- Vol. 40 (4) , 533-539
Intravenous Synthetic Secretin Reduces the Incidence of Pancreatitis Induced by Endoscopic Retrograde Cholangiopancreatography
This study aimed to evaluate whether synthetic secretin is effective in reducing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. This is a single academic medical center, prospective, randomized, double-blind, placebo-controlled trial using secretin (dose of 16 μg) administered intravenously immediately before ERCP. Patients were evaluated for the primary outcome of post-ERCP pancreatitis as diagnosed by a single investigator. A total of 1100 patients were screened, of whom 869 were randomly assigned to receive secretin (n = 426) or placebo (n = 443) before ERCP and were evaluated after the procedure for efficacy of secretin. The incidence of pancreatitis in the secretin group compared with the placebo group was 36 (8.7%) of 413 patients versus 65 (15.1%) of 431 patients, respectively, P = 0.004. In the subgroup analysis, secretin was highly protective against post-ERCP pancreatitis for patients undergoing biliary sphincterotomy (6/129 vs 32/142, P < 0.001), patients undergoing cannulation of the common bile duct (26/339 vs 56/342, P < 0.001), and patients not undergoing pancreatic sphincterotomy (26/388 vs 57/403, P = 0.001). Analysis of the interaction between these groups reveals that the primary effect of secretin prophylaxis was prevention of post-ERCP pancreatitis in patients undergoing biliary sphincterotomy. Synthetic secretin reduces the risk of post-ERCP pancreatitis, particularly in patients in undergoing biliary sphincterotomy.
- 1 July 2004
- Vol. 5 (4) , 225-30
A wolf in sheep's clothing: a non-functioning islet cell tumor of the pancreas masquerading as a microcystic (serous cystic) adenoma.
The endosonographic appearance of a microcystic "honeycomb" lesion of the pancreas usually indicates a serous cystic adenoma. We report a case of a non-functioning islet cell tumor that has the typical microcystic "honeycomb" appearance of a serous cystic adenoma. The implications for endoscopic ultrasound diagnosis and management of cystic pancreatic lesions are discussed. Islet cell tumors are a rare differential diagnosis of microcystic pancreatic lesions. If fine needle aspiration remains non-diagnostic preoperative distinction from serous cystic adenomas may be impossible.
- 1 July 2004
- Vol. 5 (4) , 225-30
A wolf in sheep's clothing: a non-functioning islet cell tumor of the pancreas masquerading as a microcystic (serous cystic) adenoma.
The endosonographic appearance of a microcystic "honeycomb" lesion of the pancreas usually indicates a serous cystic adenoma. We report a case of a non-functioning islet cell tumor that has the typical microcystic "honeycomb" appearance of a serous cystic adenoma. The implications for endoscopic ultrasound diagnosis and management of cystic pancreatic lesions are discussed. Islet cell tumors are a rare differential diagnosis of microcystic pancreatic lesions. If fine needle aspiration remains non-diagnostic preoperative distinction from serous cystic adenomas may be impossible.
- 1 May 2004
- Vol. 5 (3) , 122-31
Outcome of endoscopic minor papillotomy in patients with symptomatic pancreas divisum.
Pancreas divisum has been associated with recurrent acute pancreatitis, chronic abdominal pain without elevated pancreatic enzymes, and chronic pancreatitis. Prior studies suggest that endoscopic minor papillotomy benefits certain symptomatic pancreas divisum patients. However, the data are quite limited and there is a lack of long-term follow-up. To describe a retrospective study of endoscopic minor papillotomy for pancreas divisum. Eighty-nine adult patients who underwent endoscopic minor papillotomy at our referral center were included in the study. Median follow-up was 29 months. We conducted a telephone survey. Fifty-three patients were available for the telephone survey. Thirty-two patients (60.4%) reported immediate improvement: however, symptoms recurred in 17 (53.1% of the immediate responders). Repeat endoscopic interventions were performed in 8 patients, with long-term improvement in two. Overall long-term improvement was achieved in 17 patients (32.1%). Results of minor papillotomy were more favorable for patients with recurrent, well-defined bouts of pancreatitis (immediate improvement: P=0.036; long-term improvement: P=0.064) compared to those with pancreatitis who reported continuous pain and those without clinical evidence of pancreatitis (immediate improvement: 73.3%, 42.9% and 44.4%, respectively; long-term improvement: 43.3%, 21.4%, and 11.1%, respectively). The long-term benefit from endoscopic minor papillotomy using strict criteria is poorer than suggested from previous studies. However, pancreas divisum patients with well-defined bouts of pancreatitis are more likely to benefit from endoscopic minor papillotomy than those without symptom-free intervals between "attacks" and those with pain that is not associated with elevated pancreatic enzymes.
- 1 May 2004
- Vol. 5 (3) , 122-31
Outcome of endoscopic minor papillotomy in patients with symptomatic pancreas divisum.
Pancreas divisum has been associated with recurrent acute pancreatitis, chronic abdominal pain without elevated pancreatic enzymes, and chronic pancreatitis. Prior studies suggest that endoscopic minor papillotomy benefits certain symptomatic pancreas divisum patients. However, the data are quite limited and there is a lack of long-term follow-up. To describe a retrospective study of endoscopic minor papillotomy for pancreas divisum. Eighty-nine adult patients who underwent endoscopic minor papillotomy at our referral center were included in the study. Median follow-up was 29 months. We conducted a telephone survey. Fifty-three patients were available for the telephone survey. Thirty-two patients (60.4%) reported immediate improvement: however, symptoms recurred in 17 (53.1% of the immediate responders). Repeat endoscopic interventions were performed in 8 patients, with long-term improvement in two. Overall long-term improvement was achieved in 17 patients (32.1%). Results of minor papillotomy were more favorable for patients with recurrent, well-defined bouts of pancreatitis (immediate improvement: P=0.036; long-term improvement: P=0.064) compared to those with pancreatitis who reported continuous pain and those without clinical evidence of pancreatitis (immediate improvement: 73.3%, 42.9% and 44.4%, respectively; long-term improvement: 43.3%, 21.4%, and 11.1%, respectively). The long-term benefit from endoscopic minor papillotomy using strict criteria is poorer than suggested from previous studies. However, pancreas divisum patients with well-defined bouts of pancreatitis are more likely to benefit from endoscopic minor papillotomy than those without symptom-free intervals between "attacks" and those with pain that is not associated with elevated pancreatic enzymes.
- 1 December 2001
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 8 (10) , 758-765
Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas
- 1 December 2001
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 8 (10) , 758-765
Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas
- 27 December 2000
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (12) , 1679-1684
A double-blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin
- 27 December 2000
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (12) , 1679-1684
A double-blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin
- 1 April 2000
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 51 (4) , AB302
7237 Bile leaks after t-tube removal in orthotopic liver transplantation patients: the role of ercp.
- 1 April 2000
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 51 (4) , AB302
7237 Bile leaks after t-tube removal in orthotopic liver transplantation patients: the role of ercp.
- 1 April 2000
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 51 (4) , AB185
4618 Precut papillotomy has a low complication rate in experienced hands: a 6-year retrospective review from a specialist center.
- 1 April 2000
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 51 (4) , AB185
4618 Precut papillotomy has a low complication rate in experienced hands: a 6-year retrospective review from a specialist center.